LOS ANGELES–(BUSINESS WIRE)–January 18, 2022–
BiologyWorks™, Inc., a digital healthcare platform company, today announced that a substantial clinical trial of its portable, reusable molecular test for COVID-19 achieved 99.1% accuracy. laboratory RT-PCR tests.
This press release is multimedia. See the full version here: https://www.businesswire.com/news/home/20220116005038/en/
k (now) portable molecular testing device (Photo: Business Wire)
The independent clinical trial, conducted by Locus Medicus in Athens, Greece, prospectively tested 330 patients with symptomatic and asymptomatic cases of COVID-19. For the study, clinical laboratory staff collected two bilateral anterior nasal swabs from each patient. Immediately after collection, one swab was tested in the laboratory’s standard CE-Mark RT-PCR test and the other swab was tested by BiologyWorks k (now). BiologyWorks k(now) molecular test results were 99.1% overall percent agreement with RT-PCR laboratory test results.
In addition to the clinical trial conducted by Locus Medicus, other independent validation studies of BiologyWorks k(now) have been conducted by the University of California, Los Angeles (UCLA), County of Los Angeles and Streeklab in Haarlem, the Netherlands. . Additionally, the company has verified the effectiveness of BiologyWorks k(now) with over 12,000 tests in its Southern California lab. These studies also confirm that the BiologyWorks k(now) COVID-19 Molecular Test provides lab-quality RT-PCR results.
“Our company’s priority is to make quality laboratory testing accessible, accurate and affordable for everyone,” said Hunt Ramsbottom, CEO of BiologyWorks. “These clinical trials confirm that our portable, reusable test is among the most accurate for COVID-19.” Hunt continued, “We offer individuals and providers a highly reliable testing platform with a significantly lower cost per result and faster time to results.”
BiologyWorks’ molecular test works in conjunction with the k(now) PRO™ digital platform, which provides point-of-care (POC) providers with a complete solution for end-to-end test management. POC providers and patients simultaneously receive verified results within 45 minutes, putting individuals in control of their health data. The BiologyWorks k(now) PRO digital platform complies with the highest privacy standards, including the Health Insurance Portability and Accountability Act (HIPAA) and the EU General Data Protection Regulation (GDPR).
BiologyWorks™ ( www.biologyworks.com ) is the creator of the BiologyWorks k(now)™ molecular test and the k(now) PRO™ digital platform. Together, these products offer point-of-care providers a complete solution for highly accurate and affordable end-to-end test management. The company’s chemistry is patent-protected, based on research from the Alfred Mann Foundation, and is backed by a grant from the Bill & Melinda Gates Foundation.
For all commercial enquiries, please contact: [email protected]
Show source version on businesswire.com:https://www.businesswire.com/news/home/20220116005038/en/
CONTACT: Nancy Perlman
KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: MEDICAL SUPPLIES MEDICAL DEVICES HEALTH INFECTIOUS DISEASES CLINICAL TRIALS BIOTECHNOLOGY
SOURCE: BiologyWorks, Inc.
Copyright BusinessWire 2022.
PUBLISHED: 01/18/2022 07:00 / DISK: 01/18/2022 07:02